U.S. National Phase Application of PCT/GB2004/001072 Preliminary Amendment – Crothers et al.

Page 3

Amendments to the Claims:

Before claim 1 on page 17 insert -- We claim:--

This listing of claims will replace all prior versions, and listings, of claims in the

application:

Listing of Claims:

(Currently Amended) A composition comprising: 1.

a pharmaceutically active compound and a non-encapsulating adjuvant, wherein the

adjuvant comprises a fungal cell or a fragment thereof.

(Original) A composition as claimed in claim 1, wherein the fungal cell fragment 2.

comprises a fungal cell wall or a part thereof.

(Currently Amended) A composition as claimed in claims 1-or 2, wherein the 3.

pharmaceutically active compound comprises a hydrophilic moiety.

(Currently Amended) A composition as claimed in claim 3[,] wherein the 4.

pharmaceutically active compound is hydrophilic or substantially hydrophilic.

{00085114.DOC/} Your Ref.: P409224US

Our Ref.: 833.012

U.S. National Phase Application of PCT/GB2004/001072

Preliminary Amendment – Crothers et al.

Page 4

(Currently Amended) A composition as claimed in claim 3-or 4, wherein the 5.

pharmaceutically active compound comprises a peptide.

(Currently Amended) A composition as claimed in claim 5[,] further comprising 6.

proteinase inhibitor.

(Currently Amended) A composition as claimed in any one of the preceding claims claim 7.

1, wherein the fungal cell or fungal cell fragment is derived from one or more fungi selected

from the group consisting of Mastigomycotina, Zygomycotina, Ascomycotina, Basidiomycotina

andDezitero7izycotina.

(Currently Amended) A composition as claimed in claim 7[,] wherein the fungal cell or 8.

fungal cell fragment is derived from Ascomycotina.

(Currently Amended) A composition as claimed in claim 8[,] wherein the fungal cell or 9.

fungal cell fragment is derived from yeast.

{00085114.DOC/} Your Ref.: P409224US Our Ref.: 833.012

U.S. National Phase Application of PCT/GB2004/001072

Preliminary Amendment – Crothers et al.

Page 5

10. (Currently Amended) A composition as claimed in claim 9[,] wherein the fungal cell or

fungal cell fragment is derived from one or more selected from the group consisting of

Candidaalbicans, Blastomycesdermatitidis, Coccidioidesimmitis, Hispltoplasma capsulatum,

Paracoccidioides brasiliensis, Penicillium marneffei and Saccharomyces cerevisiae.

11. (Currently Amended) A composition as claimed in claim 10[,] wherein the fungal cell or

fungal cell fragment is derived from Saccharomyces cerevisiae.

12. (Currently Amended) A composition as claimed in any one of the preceding claims claim

10, wherein the fungal cell or fungal cell fragment contains chitin and/or chitosan.

13. (Original) A composition as claimed in claim 12, wherein the fungal cell or fungal cell

fragment contains chitin in an amount of at least about 5% by dry weight.

14. (Currently Amended) A composition as claimed in claim 12-or-13-, wherein the fungal

cell or fungal cell fragment contains chitosan in an amount of at least about 5% by dry weight.

15. (Currently Amended) A composition as claimed in any one of the preceding claims

claim 12, wherein the pharmaceutically active compound is absorbed via the paracellular

pathway.

{00085114.DOC /} Your Ref.: P409224US Our Ref.: 833.012 U.S. National Phase Application of PCT/GB2004/001072 Preliminary Amendment – Crothers et al.

Page 6

16. (Currently Amended) A composition as claimed in any one of the preceding claims claim 12, wherein the adjuvant is present in an amount effective to increase the permeability of the paracellular pathway in vivo.

17. (Currently Amended) A pharmaceutical composition comprising a composition as claimed in any one of the preceding claims land a pharmaceutically active compound encapsulated within a yeast cell.

18. (Currently Amended) A composition as claimed in any one of the preceding claims claim 1 for use as a medicament.

19. (Original Currently Amended) A packaged composition comprising:
 at least two discrete components, the first component comprising a pharmaceutically active composition and the second component comprising a fungal cell or a fragment thereof.

20. (Currently Amended) A method of administering a pharmaceutically active compound via the paracellular pathway comprising the use of a composition as claimed in any one of claims 1-16claim 1.

{00085114.DOC /} Your Ref.: P409224US Our Ref.: 833.012 U.S. National Phase Application of PCT/GB2004/001072 Preliminary Amendment – Crothers et al. Page 7

- 21. (Original) The use of a non-encapsulating fungal cell or fungal cell fragment to augment the bioavailability of a pharmaceutically active compound.
- 22. (Currently Amended) The use of a composition as claimed in any one of claims l
 16claim 1 for alleviating the symptoms of and/or curing an ailment or disease.

{00085114.DOC /} Your Ref.: P409224US Our Ref.: 833.012